CLOs on the Move

BigHat Biosciences

www.bighatbio.com

 
BigHat`s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Leslie Grab
Vice President, Intellectual Property and Legal Profile

Similar Companies

Retia Medical

Retia Medical provides accurate, simple, low-cost cardiac output monitoring.

FFF Enterprises Inc

FFF Enterprises Inc is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cardior Pharmaceuticals

Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.

Innovation

Innovation is the leading provider of Pharmacy Intelligence™ and pharmacy automation to the retail, hospital, government, and mail order pharmacy markets. Our PharmASSIST® suite of pharmacy automation and process optimization solutions enable all types of pharmacies to increase operational efficiency, enhance patient safety, and provide a higher quality of patient care. Leveraging our unparalleled Pharmacy Intelligence, you can optimize your pharmacy fulfillment process, develop a proven ROI, and gain complete confidence in your automation decisions before investing. Innovation is a name we carry proudly. It is what we do and in many ways who we are. For three and a half decades we have been bringing new technology to industry. Our approach is simple. We start by understanding the problem and then apply all of our talent, expertise, and resources to create new and inventive ways to solve them. That is Innovation.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.